Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences, a leader in cell analysis solutions, announced that underwriters fully exercised their option to purchase an additional 2,184,695 shares at $17.00 per share. This brings the total shares sold in its recent IPO to 16,749,330, generating $237 million in gross proceeds before expenses. The IPO, completed on July 27, 2021, included shares sold by both Cytek and certain stockholders. Joint book-running managers for the offering were Morgan Stanley, Goldman Sachs, Piper Sandler, and Cowen.
Cytek Biosciences announced the closing of its initial public offering, raising $200 million by selling 14,564,635 shares at $17.00 per share. The offering included 11,764,706 shares from Cytek and 2,799,929 shares from selling stockholders. Cytek did not receive proceeds from the latter. Additionally, underwriters were granted a 30-day option to purchase 2,184,695 shares to cover over-allotments. Shares are traded on Nasdaq under the symbol CTKB.